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Abstract: Objectives: For women who suffer from systemic lupus erythematosus (SLE), pregnancy can be a concern, 
placing the mother and fetus at risk. Our objectives were to assess the risk of adverse pregnancy outcome, disease flares, 
fertility rate, and co-morbidities in SLE women compared to healthy controls. We also systematically reviewed the litera-
ture available on pregnancy outcome in SLE to compare our results to other published data. Our hypothesis was that preg-
nancy outcome in SLE is improving over time. 
Methods: A case-control study comparing self-report of the above-mentioned parameters in SLE (N=108) vs healthy con-
trols or patients with non-inflammatory musculoskeletal (MSK) disorders (N=134) was performed. Data were collected 
using a self-administered questionnaire. Proportions, means and odds ratios were calculated. We searched and quantified 
the literature on pregnancy outcome, lupus reactivation and fertility rate. Data were summarized and presented in mean % 
± SEM and median % with interquartile range (IQR). 
Results: Gynecological history, fertility rate and age at first pregnancy in SLE patients were comparable to controls. 
Eighteen percent of SLE patients reported a flare and 18% reported an improvement of symptoms during pregnancy. 
Twenty-four percent of lupus patients had at least one preterm delivery vs 5% in controls (OR =8.32, p = 0.0008), how-
ever other pregnancy outcomes (miscarriage, therapeutic abortion, stillbirth and neonatal death rate) did not differ be-
tween the groups. Thyroid problems were reported to be more likely in SLE patients (p = 0.02), but the prevalence of 
other co-morbidities was similar to controls. A literature review demonstrated that fertility was not affected in SLE pa-
tients. Lupus reactivations are common during pregnancy (36.5% ± SEM 3.3%). Most agreed that SLE pregnancies had 
more fetal loss (19.5% ± SEM 1.6%) and preterm births (25.5% ± SEM 2.2%) when compared to the general population. 
Over time, the rate of SLE peripartum flares has improved (p = 0.002) and the proportion of pregnancies resulting in live 
birth has increased (p = 0.024). The frequency of fetal death has not significantly changed. Our findings from the case-
control study were, in general, consistent with the literature including the frequency of fetal death, neonatal death, live 
births and pregnancy rate. 
Conclusion: Prematurity (25.5% ± SEM 2.2%) and fetal death (19.5% ± SEM 1.6%) in SLE pregnancy are still a concern. 
However, new strategies with respect to pregnancy timing and multidisciplinary care have improved maternal and fetal 
outcome in SLE. 
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INTRODUCTION 
  Systemic lupus erythematosus (SLE) is a serious multi-
system disease affecting predominantly women of childbear-
ing age. Fertility of SLE patients is usually comparable to 
the general population. There have been improved outcomes 
and survival in SLE. Likewise, adequate obstetrical care and 
perinatal management might ensure a better pregnancy out-
come. 
  Historically, fetal and maternal well being of patients 
with SLE seemed to be compromised to the extent that the 
medical community recommended against pregnancy in SLE 
patients. It was difficult to assess whether superimposing 
pregnancy was detrimental as the clinical outcome of non-
pregnant SLE patients was poor [1, 2]. It seems that with 
better control of disease activity, pregnancy in SLE patients  
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is no longer an absolute contraindication. However, fetal and 
maternal complications still exist. Careful planning of preg-
nancy coupled with multidisciplinary monitoring and treat-
ment substantially decreases the risks for the mother and the 
infant [3]. 
  In this article we report a case-control study on preg-
nancy outcome, disease flares, fertility rate, and co-
morbidities comparing SLE patients vs healthy controls or 
patients with non-inflammatory musculoskeletal (MSK) dis-
orders using a self-report questionnaire. We also compare 
our results to the current literature using a systematic quanti-
tative approach. Our hypothesis was that pregnancy outcome 
is improving over time in SLE. 
MATERIALS AND METHODOLOGY 
  A four-page questionnaire was sent to subjects with SLE 
and either healthy control subjects solicited from a newspa-
per advertisement or subjects who had non-inflammatory 
MSK disorders such as osteoarthritis, tendonitis and fi-
bromyalgia. SLE patients and MSK patients were recruited 90    The Open Rheumatology Journal, 2008, Volume 2  Yuen et al. 
from a single rheumatology clinic. This questionnaire con-
tained 44 questions on socio-demographics and pregnancy 
history, and was approved by the Health Sciences Research 
Ethics Board of the University of Western Ontario, London, 
Ontario, Canada. All SLE patients met the American College 
of Rheumatology (ACR) criteria [4]. All subjects were 
blinded as to the hypothesis and were sent the questionnaire 
packages. Two follow-ups were sent to non-respondents. 
  Statistical analysis of the data was performed using JMP 
Statistical Discovery Software (SAS Institute, Cary, NC, 
USA). For each survey question, unanswered questions were 
excluded from the analyses. Group means, proportions, odds 
ratios (OR) and 95% confidence intervals (CI) were calcu-
lated. Statistical significance was accepted at p  0.05. 
Analyses were redone after adjusting for age. 
  We also assessed laboratory results for antinuclear anti-
body (ANA), anti-double-stranded DNA (anti-dsDNA) anti-
bodies and antiphospholipid antibodies (anticoagulant and 
anticardiolipin) in 36 patients from our lupus cohort. Stan-
dard assays were used for each type of antibody: im-
munofluorescent antinuclear antibody (ANA or FANA) test; 
ELISA for anti-dsDNA; lupus anticoagulant panel (activated 
partial thromboplastin time [aPTT] and modified Russell 
viper venom time [RVVT], platelet neutralization procedure 
[PNP] or kaolin clotting time [KCT], etc., as appropriate); 
and ELISA for anticardiolipin antibodies. 
  A review of the literature on pregnancy outcome in SLE 
was performed. Original articles on fertility rate, lupus flares 
during pregnancy, prematurity and fetal losses were selected. 
The search was conducted using the Pubmed database avail-
able at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB= 
pubmed. Terms used (in various combinations) were: sys-
temic lupus erythematosus, pregnancy outcome, lupus preg-
nancy, fertility rate, prematurity, preterm delivery, fetal loss, 
fetal wastage (referred to as fetal death in this paper), fetal 
outcome, spontaneous abortions,  miscarriage, intrauterine 
growth restriction, lupus flares, lupus nephritis. Due to the 
vast amount of literature available, some older and smaller 
studies were not included. Data reported from each article on 
pregnancy outcome, including fertility, parity, elective abor-
tions, miscarriages, fetal loss, neonatal death, preterm or full 
birth rates and lupus flares were recorded. We calculated the 
mean % ± SEM and median % with interquartile range 
(IQR) for each subject. We then classified these articles into 
3 subgroups according to their publication date to assess 
temporal trends. Findings were summarized and compared to 
those obtained from our case-control study. 
RESULTS  
  The response rate was 72% for SLE subjects and 69% for 
controls. The mean age of SLE subjects was 42 ± SEM 1 
years vs 38 ± SEM 1 years for controls. Controls were more 
likely to continue their education above high school (p = 
0.0001), and lupus patients were more likely to be home-
makers (p = 0.01). In terms of marital status, there were no 
differences between the groups. All data are summarized in 
Table 1. 
  Eighty-three patients (77%) in the SLE group (N=108) 
had at least one pregnancy vs 93 (69%) in the control group 
(N=134). Sixty-seven (> 60%) SLE patients were pregnant 
prior to SLE diagnosis. Twenty-six of 83 SLE-women (31%) 
had at least one miscarriage. Pregnancy was associated with 
a self-reported SLE flare in 18% of patients; however, 18% 
of patients also reported improvement. The number of preg-
nancies per woman was similar between the groups (2.3 ± 
0.2 for SLE and 1.8 ± 0.1 for controls; p = 0.17). SLE pa-
tients and controls had a similar age of first pregnancy. 
Twenty-four percent of lupus patients had at least one pre-
term delivery vs 5% in controls (OR = 8.32, p = 0.0008), but 
the pregnancy outcome was otherwise comparable (such as 
miscarriages, perinatal mortality). Thyroid problems (mainly 
hypothyroidism) were reported more in lupus patients (21% 
vs 10%, p = 0.02), but the frequency of other co-morbidities 
was similar to controls, such as hypertension (13% vs 21%, p 
= 0.1) and diabetes mellitus (2% vs 4%, p = 0.27). SLE pa-
tients were more likely to smoke during pregnancy (42% vs 
24%, OR = 2.35, p = 0.009). Gynecological history including 
age at menarche and menopause, and frequency of irregular 
periods did not differ between the groups. SLE patients re-
ported a shorter duration of oral contraceptive (OCP) use, 
and no difference in postmenopausal hormone replacement 
therapy use as compared to controls. 
  When adjusted for age, data were not different from 
those presented in Table 1, except age at menopause (p = 
0.02). Also, SLE women were less likely to use any contra-
ception (11% vs 4%, p = 0.03) and used OCP in similar 
numbers but for a shorter duration (56 vs 72 months, p = 
0.0001). When adjusting for smoking on preterm birth, the 
relationships reported did not substantially change. 
  Our SLE cohort was primarily Caucasian, English speak-
ing and fairly healthy. Ninety-five percent of our population 
was women, the mean age was 49.1 ± SEM 1.3 years and the 
mean disease duration was 11.4 ± SEM 1.3 years. The mean 
± SEM SLAM [5], SLICC [6] and SLEDAI [7] scores were, 
respectively, 8.5 ± 0.3, 1.3 ± 0.4 and 6.7 ± 0.4. 
  We assessed laboratory data from 36 patients in our SLE 
population: 92% had positive ANA, 56% were positive for 
anti-double-stranded DNA (anti-dsDNA) and 21% had an-
tiphospholipid antibodies. 
REVIEW OF THE LITERATURE 
  In total, 54 articles on lupus pregnancy published from 
1963 to 2006 were reviewed [8-61]. Table 2 presents the 
results from the previously published studies compared to 
our present case-control study findings. Most of the results 
were similar between groups; however, we found that SLE 
flares (by self report) during pregnancy were less frequent in 
our population compared to the literature. Also, fewer pa-
tients from our study had prematurity or elective termination. 
Figs. (1, 2) show results in median (%) for pregnancy out-
come and SLE peripartum flares subdivided into 3 periods of 
publication date. Each time frame contains data from 18 pub-
lications. We noticed that over time, the rate of SLE peripar-
tum flares has improved (p = 0.002), elective abortions (in-
cluding termination for medical or personal reasons) have 
decreased, and the proportion of pregnancies resulting in live 
birth has increased (p = 0.024). The frequency of fetal death 
(the sum of spontaneous abortions or miscarriage and still-
births) has not significantly changed. Results in mean (%) 
and median (%) were similar (Table 3). 
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Table 1.  Subjects` Characteristics and Results of Our Case-Control Study  
 
  SLE N (%)  Controls N (%)  p-Value  OR  CI 95% 
N 108    134   
Age (years)  42 ± 1  38 ± 1  0.37 
 
Disease Duration (years)  15 ± 1   
Educational level 
High school 
Above high school 
 
52 (48) 
56 (52) 
 
26 (19) 
108 (81) 
 
0.0001 
 
0.26 
 
 
2.18-6.83 
Marital Status 
Never married 
Married, Living Common-law, Widowed 
Separated, Divorced, Remarried 
 
15 (14) 
77 (71) 
16 (15) 
 
25 (19) 
84 (62) 
25 (19) 
 
0.36 
 
Work experience 
Homemaker 
Working/Student 
 
21 (21) 
81 (79) 
 
11 (9) 
115 (91) 
 
0.01 
 
2.7   1.24-5.93 
 
Ever pregnant   83 (77)  93 (69)  0.15  1.5  0.85-2.73 
Symptoms before last pregnancy 
Yes 
No 
Unknown 
 
25 (30) 
55 (66) 
3 (4) 
 
DM   4 (4)  2 (1.5)  0.28     
Hypertension  23 (22)  18 (13)  0.10  1.76  0.90-3.48 
Thyroid Problems   23 (21)  14 (10)  0.02  2.32  1.13-4.77 
Other Medical Problems   57 (54)  57 (43)  0.09  1.55  0.93-2.59 
Onset of menarche (years)  12.6 ± 0.1  12.2 ± 0.2  0.07   
Menopausal   40 (38)  32 (24)  0.02   1.93  1.11-3.38 
Age at menopause *  42 ± 1  43 ± 2  0.37     
Hysterectomy causing menopause in above group (%)  21 (47)  12 (39)  0.29  1.39  0.55-3.51 
Hormone replacement therapy (ever used during meno-
pause) 
29 (66)  14 (47)  0.10  2.21  0.85-5.71 
Irregular periods in non-menopausal  10 of 44 (22)  5 of 29 (17)  0.57  1.4  0.43-4.7 
Mean age at 1st pregnancy (years)  23 ± 1  24 ± 1  0.06   
Number of pregnancies per woman  2.3 ± 0.2  1.8 ± 0.1  0.17   
Number of children   2.33 ± 0.1  2.05 ± 0.1  0.72   
Had child (ren) (% out of those pregnant)  78 (93)  89 (95)  0.60   
No children  5 (5)  4 (5)  0.74     
Miscarriage (at least one)  26 (31)  28 (30)  0.86  0.94  0.50-1.79 
Therapeutic abortion   7 (8)  8 (8)  0.53  1.03  0.36-2.99 
Ever had a stillborn child   1 (1)  0 (0)  0.22   
Neonatal death (<3 months)   4 (5)  1 (1)  0.13   
At least one preterm birth  20 (24)  5 (5)  0.0008  8.32 3.06-22.66 
Gestational Diabetes  7 (9)  5 (5)  0.42  1.62  0.49-5.33 
High blood pressure / Toxemia during pregnancy   23 (28)  20 (22)  0.36  1.38  0.69-2.75 
Smoked during pregnancy   35 (42)  22 (24)  0.009  2.35  1.23-4.49 
Alcohol during pregnancy   5 (6)  10 (11)  0.26  0.53  0.17-1.62 
Other health problems during pregnancy   30 (37)  24 (26)  0.11  1.69  0.89-3.23 92    The Open Rheumatology Journal, 2008, Volume 2  Yuen et al. 
Table  2.  Summary of Pregnancy Outcomes, Fertility Rate 
and Flares Presented in Mean (%) ± SEM from Pub-
lished Studies Compared to Our Present Case-
Control Study Findings 
 
   N  Literature  
Review 
Present  
Study-SLE  
Cases 
Present  
Study-Controls 
Elective termination  
(%) 
44  10.5 ± 1.5  2.9  4.0 
Fetal wastage (%)  45  19.5 ± 1.6  18.3  16.6 
Neonatal death (%)  39  2.2 ± 0.4  1.7  0.4 
Preterm birth (%)  43  25.5 ± 2.2  9.5  4.9 
Full term birth (%)  44  49.0 ± 2.5  69.3  74.5 
Live birth (%)  50  72.3 ± 1.9  78.8  79.4 
Pregnancy rate  
(mean) 
7  2.3 ± 0.08  2.3 ± 0.2  1.8 ± 0.1 
Flares during  
pregnancy (%) 
38  28.6 ± 2.6  18   
Flare-up postpartum  
(%) 
24  11.9 ± 2.0     
Total flares (%)  39  36.5 ± 3.3     
IUGR (%)  20  14.8 ± 0.8     
Preg-induced HTN  
(%)  
17  15.9 ± 2.7  19.3*  17.2* 
Gestational DM  
(%) 
8  6.7 ± 1.6  7.2  5.4 
APL ab (%)  13  36.8 ± 6.1     
Neonatal lupus (%)  25  2.4 ± 0.6     
Elective termination= termination for personal or medical reasons 
Fetal wastage= sum of miscarriages or spontaneous abortions and stillborn 
IUGR= Intrauterine growth restriction 
Pregnancy rate= number of pregnancies per woman 
Preg-induced HTN = pregnancy-induced hypertension 
Gestational DM= gestational diabetes 
APL ab= antiphospholipid antibodies 
* Sum of pregnancy-induced hypertension and toxemia 
N= number of publications. 
FERTILITY RATE 
  Fertility is defined as the ability to become pregnant. 
Seven publications [12, 33, 35, 37-38, 45, 59] demonstrated 
that the fertility rate in SLE is usually unaffected and compa-
rable to the general population. Pregnancy rate (number of 
pregnancies per patient) varied from 2.0 to 2.6 (mean 2.3 ± 
SEM 0.08) (Table 2). However, certain factors predispose 
some SLE women to lower fertility. Severe renal failure and 
use of high doses of steroids might lead to menstrual irregu-
larities or even amenorrhea [62]. In addition, previous treat-
ment with alkylating agents can lead to ovarian failure [63]. 
Cyclophosphamide-induced premature ovarian failure is well 
documented. In fact, the incidence of ovarian failure is re-
lated to the age when starting cyclophosphamide, the dura-
tion of use and the cumulative dose [64-69]. In a retrospec-
tive series of 39 SLE patients who had received intermittent 
pulses of cyclophosphamide therapy,  Boumpas  et al. re-
ported that sustained amenorrhea occurred in 12% of patients 
< 25 year of age, in 27% of patients between 26 to 30 years 
old and in 62% of patients older than 31years [64]. In a study 
of 67 SLE premenopausal women who were treated with 
monthly intravenous cyclophosphamide, 31% developed 
sustained amenorrhea of at least 12 months. In this same 
study, the cumulative dose of cyclophosphamide resulting in 
sustained amenorrhea in 50% and 90% of the women (D50 
and D90) was 8 g/m
2 and 12 g/m
2, respectively [68]. 
  In order to preserve fertility and to minimize cyclophos-
phamide gonadotoxicity, an adjuvant treatment with go-
nadotropin-releasing hormone agonistic analogue (GhRH-a) 
may be an option [70-71], although this is not widely 
adopted. Some clinics use oral contraceptive pills to prevent 
ovulation as theoretically having less risk to an anovulatory 
ovary. There are trials of exogenous estrogen and lupus flare, 
and both contraceptive hormones and post menopausal hor-
mones in RCTs seem to be relatively safe. There are some 
contraindications for hormone use in young women with 
lupus such as known hypercoaguable state, and some relative 
contraindications such as migraines, hypertension and smok-
ing [72, 73]. 
 
 (Table 1) contd….. 
  SLE N (%)  Controls N (%)  p-Value  OR  CI 95% 
SLE flare during pregnancy   10 (18) 
SLE improved during pregnancy   10 (18) 
As defined by patients 
Contraception use (ever, any, including OCP)   96 (89)  128 (96)  0.03  0.31  0.11-0.92 
OCP use   66 (49)  47 (44)  0.38  0.8  0.48-1.32 
Duration of OCP use (mean ± SEM in months)  56 ± 5.7  72 ± 5.5  0.0001    0.58-0.65 
Tubal Ligation   33 (32)  30 (23)  0.11  1.60  0.89-2.85 
At least 6 months of infertility   32 (33)  41 (32)  0.88  1.04  0.59-1.83 
Unable to have children because of infertility   18 (19)  30 (24)  0.38   0.75  0.39-1.44 
Ever taken fertility medications   5 (5)  5 (4)  0.73  1.25  0.35-4.44 
Infertility problems – partner 
Yes 
No 
Not known 
 
5 (5) 
63 (64) 
31 (31) 
 
6 (5) 
74 (59) 
45 (36) 
 
0.76 
 
0.98 
 
0.29-3.36 
Results are given in % or mean ± SEM, unless indicated otherwise. 
OR= odds ratios: SLE vs controls 
OCP= oral contraceptive pills 
*Most were not menopausal, so age should increase over time Pregnancy in SLE  The Open Rheumatology Journal, 2008, Volume 2    93 
   
 
Fig. (1). The frequency of SLE peripartum flares in the literature prior to 1990 vs most recent data. 
 
Fig. (2). The frequency of SLE pregnancy outcomes in the literature prior to 1990 vs most recent data. 
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PREGNANCY OUTCOME 
  Various publications have reported an increased inci-
dence of prematurity, fetal death (the sum of spontaneous 
abortions or miscarriage and stillbirths) and intrauterine 
grown retardation (IUGR) in SLE. Dhar et al. reviewed 16 
studies on pregnancy outcomes before and after the diagno-
sis of SLE [74] and found that, in spite of some limitations in 
study design and statistical analysis and variations in termi-
nology used, most studies concluded that pregnancy loss [8, 
21, 31, 34, 35, 37, 38, 48, 50, 56, 51, 70, 71,74], preterm 
births [8, 21, 31, 34, 38, 48, 49, 51, 74,] and IUGR [8, 31, 
33, 34] were more common after than before the diagnosis of 
SLE and compared to a control population. 
  From our review of 45 studies [9-15, 17-30, 32-34, 36, 
39, 40, 42, 45-61], the frequency of fetal death varied from 
4% to 43% (mean 19.5% ± SEM 1.6%) (Table 2), which is 
higher than in the general population [21, 31, 32, 35, 37]. In 
another study, the authors reported a 4-fold increase in the 
risk of stillbirth in lupus patients. They also found that the 
risk was halved if they excluded patients with central nerv-
ous system (CNS) disease [74]. Further investigation is 
needed to confirm this correlation in lupus pregnancy. Sev-
eral factors may predict fetal death such as lupus disease 
activity, active lupus nephritis [22], and the presence of an-
tiphospholipid antibodies. 
  Fetal prognosis depends mostly on disease activity, with 
fetal loss ranging from 25-52% in patients with active SLE 
compared to 8-12% in patients with inactive SLE at the onset 
of pregnancy. The latter rate is comparable to observations in 
healthy women [17-21]. 
  Active renal disease has been associated with 8-24% of 
fetal loss from miscarriages [23] and 4-24% of stillbirths and 
neonatal deaths [17, 19, 22-25]. Thus, active lupus nephritis 
patients are often advised to avoid pregnancy. However, dur-
ing inactive SLE, the pregnancy outcome is usually favor-
able [17, 19]. Rahman et al. reported on a series of 141 SLE 
pregnancies where maternal active renal disease was present 
in 33% of pregnancies resulting in fetal loss vs 13% of preg-
nancies with live births (p < 0.012) [22]. In SLE patients a 
history of nephritis, maternal hypertension (OR 6.4), prote-
inuria > 0.5g/day (OR 13.3) and the presence of antiphos-
pholipid antibodies (OR 17.8) have been shown to be predic-
Table 3.  Literature Summary: SLE Peripartum Flares and Pregnancy Outcomes Presented in Mean % ± SEM and Median % 
with Interquartile Range (IQR) for Each Time Period 
 
     N  Mean ± SEM %  Median ± IQR %  p-Value Between Groups 
<1990  13  25.9 ± 2.9  25.0 ± 10.4 
1991-1998  11  41.8 ± 4.8  44.4 ± 25.6  Flares during pregnancy 
>1999  14  20.7 ± 4.0  16.0 ± 9.1 
0.002 
<1990  8  16.3 ± 4.0  15.0 ± 22.3 
1991-1998  8  13.3 ± 3.4  11.8 ± 16.23  Flare-up postpartum 
>1999  8  6.3 ± 2.2  6.6 ± 10.1 
NS 
<1990  13  35.9 ± 5.0  34.0 ± 27.2 
1991-1998  12  51.4 ± 6.0  52.5 ± 31.1  Total flares 
>1999  14  24.3 ± 4.1  20.5 ± 20.0 
0.002 
<1990  13  15.3 ± 2.5  15.6 ± 13.4 
1991-1998  14  9.7 ± 2.5  7.9 ± 10.7  Elective termination 
>1999  17  7.5 ± 2.5  6.7 ± 9.1 
NS 
<1990  15  23.0 ± 3.5  17.9 ± 30.0 
1991-1998  13  18.9 ± 2.5  19.4 ± 15.5  Fetal wastage 
>1999  17  16.8 ± 2.1  17.0 ± 15.1 
NS 
<1990  11  19.1 ± 4.4  12.5 ± 25.3 
1991-1998  15  31.4 ± 3.5  27.0 ± 25.7  Prematurity 
>1999  17  24.5 ± 3.2  21.0 ± 17.7 
NS 
<1990  12  50.4 ± 5.7  57.5 ± 35.6 
1991-1998  15  43.3 ± 3.2  42.6 ± 25.6  Full term birth 
>1999  17  52.9 ± 4.1  53.3 ± 25.7 
NS 
<1990  16  64.9 ± 3.7  65.2 ± 23.6 
1991-1998  16  74.5 ± 2.7  75.5 ± 21.3  Live birth 
>1999  18  77.0 ± 3.1  78.2 ± 20.8 
0.024 
N= number of publications, NS=non-significant. Pregnancy in SLE  The Open Rheumatology Journal, 2008, Volume 2    95 
tive of adverse fetal outcome [20]. Another report from 
Hong Kong analyzed a subgroup of 27 patients with a past 
history of lupus nephritis; they found that significant prote-
inuria (p = 0.01) and active disease (p = 0.03) at conception 
and during the gestation were predictive of poor fetal out-
come [75]. 
  Antiphospholipid antibodies are present in 36.8% ± SEM 
6.1% of SLE patients in 13 publications [15, 16, 19-21, 26-
28, 47, 49, 52, 60, 61] (Table 2). The association between 
these antibodies and fetal loss has been well demonstrated 
[10, 23]. Mok et al. studied 91 pregnancies, reporting that 
antiphospholipid antibodies were more prevalent in patients 
with recurrent miscarriages (p = 0.008, OR = 14.3) and the 
strongest predictive factor was the presence of lupus antico-
agulant (p = 0.002, OR 23.3) [75]. Mechanisms could in-
clude lack of implantation, placental vasoconstriction and 
thrombosis leading to either fetal growth restriction or death 
[23, 76]. The literature indicates that the presence of these 
antibodies is associated with an approximately 2-fold in-
crease in fetal loss (as high as 30-83% of pregnancies com-
pared to a 4-43% fetal loss rate in antiphospholipid antibody 
negative SLE patients) [20, 23, 51, 77-78]. Fetal outcome is 
significantly improved with the use of heparin and low dose 
aspirin in these cases [79-80]. A recent review by Erkan et 
al. summarized the current evidence on the management of 
antiphospholipid syndrome in pregnancy [81]. 
  Lupus is associated with an increased rate of prematurity. 
Preterm delivery frequency in the general population varies 
between 4% and 9% [9, 23, 30, 35, 42]. Our analysis of 43 
studies found a mean of 25.5% ± SEM 2.2%, with a range of 
4% to 62% [8-16, 17-25, 27-29, 30-34, 38-40, 42-43, 46-49, 
51-60] (Table 2). The discrepancies in the literature in terms 
of frequency of prematurity in SLE might be due to differ-
ences in definitions of prematurity, the rate of therapeutic or 
spontaneous abortions and the fact that preterm birth in SLE 
has multiple causes. Reasons for prematurity seem to be SLE 
activity [9-10, 15, 32, 47, 52, 55, 75], maternal hypertension 
[15, 21, 22, 32, 82], history of fetal loss [15], pre-eclampsia 
[19], antiphospholipid antibodies [9-10, 30], placental insuf-
ficiency and an increased prevalence of premature rupture of 
the membranes [28, 83]. 
  Several studies mentioned that corticosteroid use during 
pregnancy increased the risk of preterm birth [9, 10, 15, 47, 
50, 55]. Indeed, a retrospective study demonstrated a correla-
tion between the use of > 10mg/day of prednisone in SLE 
pregnant women and an increased rate of preterm births [9]. 
However, this could be confounded by SLE disease activity. 
A study from Japan showed the frequency of preterm deliv-
ery in patients receiving > 15mg/day of prednisone was 60% 
vs 13% in patients who received 0-15mg/day (p < 0.05) [55]. 
However, a higher dosage of corticosteroid is often neces-
sary to control disease activity, which may also contribute to 
premature delivery. In addition, corticosteroids may impair 
the placental function and induce premature rupture of mem-
branes. 
  Three randomized trials have evaluated the usefulness of 
corticosteroids in pregnant women with unexplained or an-
tiphospholipid antibody-associated fetal loss. All concluded 
that corticosteroids did not improve fetal outcome. On the 
contrary, the treatment group had a significantly increased 
rate of preterm births and maternal morbidities or obstetrical 
complications such as hypertension, diabetes mellitus, pre-
eclampsia and premature rupture of the membranes [44, 84-
86]. 
  Intrauterine growth restriction (IUGR) occurs in 14.8% ± 
2.0% of SLE pregnancies in 20 studies [8, 10, 11, 15, 19, 22, 
26, 27, 30-32, 39, 42, 47, 53, 57-61]. The main factors con-
tributing to the increased rate of growth restriction are hyper-
tension [15, 22], corticosteroids, antiphospholipid antibodies 
[10, 76] and pre-eclampsia [19, 22, 36, 83, 87]. Low com-
plement levels also seem to correlate with IUGR [15, 55]. 
LUPUS FLARES 
  Diagnosis of a lupus flare in pregnancy may be difficult; 
normal physiological changes or pregnancy related compli-
cations such as pre-eclampsia can mimic a lupus flare. The 
effect of pregnancy on SLE activity has received much atten-
tion; however, the exact consequence of pregnancy on the 
course of SLE is not conclusively determined. Some authors 
have reported an increased frequency of flares [42-44], but 
others have found a rate similar to a non-pregnant SLE popu-
lation [40-41]. Differences in the definitions of lupus flare, 
as well as patient or control group characteristics might con-
tribute to these contradictory results. Overall, we found that 
lupus flares are common in pregnancy: our analysis of 39 
publications showed a mean rate of lupus reactivation of 
36.5% ± 3.3% (Table 2) [10, 11, 13, 15, 17, 18, 20, 22, 25, 
28, 32-35, 30, 42-44, 49, 53-56, 59-61]. 
  Some factors might increase the risk of flares. Most stud-
ies agreed that flares occurred more often in SLE patients 
with active disease at conception [17, 18, 54-56, 59]. A pub-
lication from Japan noted the frequency of SLE flares was 
13% in inactive patients at conception vs 75% in patients 
with active disease [55]. Moroni et al. reported fetal and ma-
ternal outcomes of 51 pregnancies in women with a history 
of lupus nephritis. They demonstrated that the only predictor 
of renal flare was the presence of any sign of renal disease 
activity at the onset of pregnancy. Indeed, renal flares oc-
curred in 5% of patients with quiescent renal disease com-
pared to 39% in patients with active renal disease (p = 0.01) 
[20]. In addition, the literature has shown that flares might 
occur in any trimester or during the post-partum period [32, 
42-44]. Usually, the severity of the flare is mild with arthri-
tis, constitutional and cutaneous manifestations being com-
mon [5, 43]. However, more serious problems affecting the 
kidneys and central nervous system have been reported in 
46% and 14% of patients, respectively [32, 42-43]. There-
fore, close monitoring and multidisciplinary care are essen-
tial during the pregnancy and post-partum period. 
  Serum prolactin normally rises early in pregnancy and 
persists at a high level through the breast-feeding period. 
Several publications have attempted to establish a relation-
ship between hyperprolactinemia and lupus disease activity, 
but results have been contradictory [88-95]. To our knowl-
edge, only one case report has been published on breast-
feeding and lupus reactivation postpartum [96]. Actually, 
there is no evidence of postpartum SLE exacerbation by 
breast-feeding. 
DISCUSSION 
  The findings from our case-control study were compared 
to those from the literature. We found no statistical differ-96    The Open Rheumatology Journal, 2008, Volume 2  Yuen et al. 
ence between the SLE vs control group for fertility rate, gy-
necological history and pregnancy outcome except for pre-
maturity (Table 1). More SLE women had preterm delivery 
compared to the control population. When we adjusted for 
possible confounding variables for each pregnancy outcome, 
we obtained a lower frequency of preterm birth and elective 
termination (Table 2). Also, lupus flares in our cohort during 
the course of pregnancy were lower than reported from the 
literature. Differences might be related to the characteristics 
of our study population, as age, ethnicity, disease status, 
treatment and personal information (such as occupation, 
education and living conditions) can influence clinic out-
comes significantly. 
  The diagnosis of SLE was confirmed for cases in our 
study but obstetrical chart review was not done. However, 
we presume the data are reliable as most women recall their 
reproductive history accurately and it is unlikely that recall 
bias will have a significant influence on the accuracy of re-
sults. Also, our results were generally consistent with the 
current literature. 
  We found that SLE subjects were more likely than con-
trols to have thyroid problems (Table 1), and thyroid disease 
is known to be more common in SLE [97-99]. We did not 
assess the temporal relationship between thyroid disease and 
SLE pregnancy, as the timing of thyroid disease onset and 
pregnancies was not determined. A limitation could be that 
many of our patients had their pregnancies prior to being 
diagnosed with SLE. 
  Other co-morbidities were similar with the exception of 
smoking during pregnancy, which was higher in SLE 
women. Education (such as counseling about conception to 
be planned while the lupus is inactive for a better outcome 
for mother and baby) and close monitoring of pregnant pa-
tients may positively impact on the outcome. Although we 
did not find smoking as a risk in our population for adverse 
pregnancy outcome, it is obvious that smoking cessation 
should be encouraged in those contemplating pregnancy and 
during pregnancy. This study was likely underpowered to 
demonstrate ill effects of smoking in lupus such as small-for-
dates babies. 
  From the 54 published papers we reviewed altogether, in 
spite of some differences in the study populations, design, 
and definitions used for pregnancy outcomes or lupus 
reactivation, we assessed in total 3740 SLE pregnancies. The 
literature showed an improvement in fetal and maternal out-
come since the last decade (Figs. 1, 2 and Table 3). Moroni 
et al. retrospectively analyzed fetal and maternal outcomes in 
SLE patients with lupus nephritis, noting that fetal loss has 
decreased from 46% to 30% since the 1970s [20]. Further-
more, treatment with heparin of patients who have antiphos-
pholipid antibodies began in 1989. A higher rate of live birth 
(71%  vs 30%) (p = 0.0013) was observed by Cortés-
Hernández et al. since the induction of this new therapy in 
these patients [10]. Obviously, important progress made in 
maternal disease control and improvements in obstetrical 
care have contributed to better fetal outcomes. 
  The are several other possible reasons that pregnancy 
outcomes may be improving over time including: less severe 
SLE over time; more mild patients being diagnosed; concep-
tion counseling about timing of pregnancy when SLE is in-
active; better multidisciplinary care; increased contraception 
use in ill patients; and a trend for better pregnancy outcome 
for all women in the general population. 
CONCLUSIONS 
  This article summarizes much of the information avail-
able on pregnancy outcomes in SLE and adds data from our 
cohort of women with SLE. Fertility is not affected in SLE 
patients; however, despite recent progress in obstetrical care, 
maternal and fetal complications still exist. Pregnancy in 
SLE patients should be considered as a high-risk pregnancy 
and conception should be planned, if possible, during a qui-
escent period. Close monitoring for optimal disease control 
and multidisciplinary obstetrical care are necessary through-
out the gestation period to increase the chances of a success-
ful pregnancy. 
REFERENCES 
[1]  Donaldson LB, De Alvarez RR. Further observations on lupus 
erythematosus associated with pregnancy. Am J Obstet Gynecol 
1962; 83: 1461-73. 
[2]  Ellis FA, Bereston ES. Lupus erythematosus associated with preg-
nancy and menopause. AMA Arch Derm Syphilol 1952; 65: 170-6. 
[3]  Cervera R, Font J, Carmona F, Balasch J. Pregnancy outcome in 
systemic lupus erythematosus: good news for the new millennium. 
Autoimmun Rev 2002; 1: 354-9. 
[4]  Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for 
the classification of systemic lupus erythematosus. Arthritis Rheum 
1982; 25: 1271-7. 
[5]  Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reli-
ability and validity of systemic lupus activity measure-revised 
(SLAM-R) for measuring clinical disease activity in systemic lupus 
erythematosus. Lupus 2001; 10: 405-9. 
[6]  Urowitz MB, Gladman DD. Measures of disease activity and dam-
age in SLE. Baillieres Clin Rheumatol 1998; 12: 405-13. 
[7]  Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alar-
con-Segovia D. Measurement of disease activity in systemic lupus 
erythematosus. Prospective validation of 3 clinical indices. J 
Rheumatol 1992; 19: 1551-8. 
[8]  Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Preg-
nancy outcomes in women with systemic lupus erythematosus. J 
Matern Fetal Med 2001; 10: 91-6. 
[9]  Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in 
women with systemic lupus erythematosus. J Rheumatol 2003; 30: 
2127-32. 
[10]  Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, 
Vilardell-Tarres M. Clinical predictors of fetal and maternal out-
come in systemic lupus erythematosus: a prospective study of 103 
pregnancies. Rheumatology (Oxford) 2002; 41: 643-50. 
[11]  Kari JA. Pregnancy outcome in connective tissue diseases. Saudi 
Med J 2001; 22: 590-4. 
[12]  Hardy CJ, Palmer BP, Morton SJ, Muir KR, Powell RJ. Pregnancy 
outcome and family size in systemic lupus erythematosus: a case-
control study. Rheumatology (Oxford) 1999; 38: 559-63. 
[13]  Sittiwangkul S, Louthrenoo W, Vithayasai P, Sukitawut W. Preg-
nancy outcome in Thai patients with systemic lupus erythematosus. 
Asian Pac J Allergy Immunol 1999; 17: 77-83. 
[14]  Kleinman D, Katz VL, Kuller JA. Perinatal outcomes in women 
with systemic lupus erythematosus. J Perinatol 1998; 18: 178-82. 
[15]  Le Thi Huong D, Wechsler B, Piette JC, Bletry O, Godeau P. Preg-
nancy and its outcome in systemic lupus erythematosus. QJM 
1994, 87: 721-9. 
[16]  Tincani A, Faden D, Tarantini M, et al. Systemic lupus erythema-
tosus and pregnancy: a prospective study. Clin Exp Rheumatol 
1992; 10: 439-46. 
[17]  Jungers P, Dougados M, Pelissier C, et al. Lupus nephropathy and 
pregnancy. Report of 104 cases in 36 patients. Arch Intern Med 
1982; 142: 771-6. 
[18]  Hayslett JP, Lynn RI. Effect of pregnancy in patients with lupus 
nephropathy. Kidney Int 1980; 18: 207-20. Pregnancy in SLE  The Open Rheumatology Journal, 2008, Volume 2    97 
[19]  Julkunen H, Kaaja R, Palosuo T, Gronhagen-Riska C, Teramo K. 
Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand 1993; 
72: 258-63. 
[20]  Moroni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. 
Am J Kidney Dis 2002; 40: 713-20. 
[21]  Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retro-
spective case-control study of the Hopkins Lupus Cohort. J Rheu-
matol 1993; 20 (4): 650-6. 
[22]  Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal 
outcome in systemic lupus erythematosus. J Rheumatol 1998; 25 
(8): 1526-30. 
[23]  Packham DK, Lam SS, Nicholls K, Fairley KF, Kincaid-Smith PS. 
Lupus nephritis and pregnancy. Q J Med 1992; 83: 315-24. 
[24]  Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in 
women with lupus nephritis. Lupus 1991; 1 (1): 19-25. 
[25]  Imbasciati E, Surian M, Bottino S, et al. Lupus nephropathy and 
pregnancy. A study of 26 pregnancies in patients with systemic lu-
pus erythematosus and nephritis. Nephron 1984; 36: 46-51. 
[26]  Englert HJ, Derue GM, Loizou S, et al. Pregnancy and lupus: 
prognostic indicators and response to treatment. Q J Med 1988; 66: 
125-36. 
[27]  Molad Y, Borkowski T, Monselise A, et al. Maternal and fetal 
outcome of lupus pregnancy: a prospective study of 29 pregnan-
cies. Lupus 2005; 14: 145-51. 
[28]  Aggarwal N, Sawhney H, Vasishta K, Chopra S, Bambery P. Preg-
nancy in patients with systemic lupus erythematosus. Aust N Z J 
Obstet Gynaecol 1999; 39: 28-30. 
[29]  Johns KR, Morand EF, Littlejohn GO. Pregnancy outcome in sys-
temic lupus erythematosus (SLE): a review of 54 cases. Aust N Z J 
Med 1998; 28: 18-22. 
[30]  Le Huong D, Wechsler B, Vauthier-Brouzes D, et al. Outcome of 
planned pregnancies in systemic lupus erythematosus: a prospec-
tive study on 62 pregnancies. Br J Rheumatol 1997; 36: 772-7. 
[31]  Julkunen H, Jouhikainen T, Kaaja R, et al. Fetal outcome in lupus 
pregnancy: a retrospective case-control study of 242 pregnancies in 
112 patients. Lupus 1993; 2: 125-31. 
[32]  Mintz G, Niz J, Gutierrez G, Garcia-Alonso A, Karchmer S. Pro-
spective study of pregnancy in systemic lupus erythematosus. Re-
sults of a multidisciplinary approach. J Rheumatol 1986; 13: 732-9. 
[33]  Nossent HC, Swaak TJ. Systemic lupus erythematosus. VI. Analy-
sis of the interrelationship with pregnancy. J Rheumatol 1990; 17: 
771-6. 
[34]  Gimovsky ML, Montoro M, Paul RH. Pregnancy outcome in 
women with systemic lupus erythematosus. Obstet Gynecol 1984; 
63: 686-92. 
[35]  Fraga A, Mintz G, Orozco J, Orozco JH. Sterility and fertility rates, 
fetal wastage and maternal morbidity in systemic lupus erythema-
tosus. J Rheumatol 1974; 1: 293-98. 
[36]  Fine L, Barnett EV, Danovitch GM, et al. Systemic lupus erythe-
matosus in pregnancy. Ann Intern Med 1981, 94: 667-677. 
[37]  McHugh NJ, Reilly PA, McHugh LA. Pregnancy outcome and 
autoantibodies in connective tissue disease. J Rheumatol 1989; 16: 
42-6. 
[38]  Siamopoulou-Mavridou A, Manoussakis MN, Mavridis AK, Mout-
sopoulos HM. Outcome of pregnancy in patients with autoimmune 
rheumatic disease before the disease onset. Ann Rheum Dis 1988; 
47: 982-7. 
[39]  Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre 
G, Piette JC. Pregnancy in past or present lupus nephritis: a study 
of 32 pregnancies from a single centre. Ann Rheum Dis 2001; 60: 
599-604. 
[40]  Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D. Lupus 
pregnancy. Case-control prospective study demonstrating absence 
of lupus exacerbation during or after pregnancy. Am J Med 1984; 
77: 893-8. 
[41]  Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. 
Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392-7. 
[42]  Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients 
with systemic lupus erythematosus. A prospective study. Arch In-
tern Med 1991; 151: 269-73. 
[43]  Petri M, Howard D, Repke J. Frequency of lupus flare in preg-
nancy. The Hopkins Lupus Pregnancy Center experience. Arthritis 
Rheum 1991; 34: 1538-45. 
[44]  Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus 
flare during pregnancy and the puerperium: a prospective study of 
78 pregnancies. Br J Rheumatol 1996; 35: 133-8. 
[45]  Kaufman RL, Kitridou RC. Pregnancy in mixed connective tissue 
disease: comparison with systemic lupus erythematosus. J Rheuma-
tol 1982; 9: 549-55. 
[46]  Tozman EC, Urowitz MB, Gladman DD. Systemic lupus erythema-
tosus and pregnancy. J Rheumatol 1980; 7: 624-32. 
[47]  Chakravarty EF, Colon I, Langen ES, et al. Factors that predict 
prematurity and preeclampsia in pregnancies that are complicated 
by systemic lupus erythematosus. Am J Obstet Gynecol 2005; 192: 
1897-904. 
[48]  Mund A, Simson J, Rothfield N. Effect of pregnancy on course of 
systemic lupus erythematosus. JAMA 1963; 183: 917-20. 
[49]  Rubbert A, Pirner K, Wildt L, Kalden JR, Manger B. Pregnancy 
course and complications in patients with systemic lupus erythema-
tosus. Am J Reprod Immunol 1992; 28: 205-7. 
[50]  Grigor RR, Shervington PC, Hughes GR, Hawkins DF. Outcome of 
pregnancy in systemic lupus erythematosus. Proc R Soc Med 1977; 
70: 99-100. 
[51]  Kiss E, Bhattoa HP, Bettembuk P, Balogh A, Szegedi G. Preg-
nancy in women with systemic lupus erythematosus. Eur J Obstet 
Gynecol Reprod Biol 2002; 101 (2): 129-34. 
[52]  Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Out-
come of lupus pregnancy: a controlled study. Rheumatology (Ox-
ford) 2000; 39: 1014-9. 
[53]  Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. 
Obstetric outcome in systemic lupus erythematosus. Semin Arthri-
tis Rheum 1995; 25: 184-92. 
[54]  Jungers P, Dougados M, Pelissier C, et al. Problems posed by 
pregnancy in women with lupus nephropathy. Presse Med 1983; 
12: 345-9. 
[55]  Kobayashi N, Yamada H, Kishida T, et al. Hypocomplementemia 
correlates with intrauterine growth retardation in systemic lupus 
erythematosus. Am J Reprod Immunol 1999; 42: 153-9. 
[56]  Bobrie G, Liote F, Houillier P, Grunfeld JP, Jungers P. Pregnancy 
in lupus nephritis and related disorders. Am J Kidney Dis 1987; 9: 
339-43. 
[57]  Wong CH, Chen TL, Lee CS, Lin CJ, Chen CP. Outcome of preg-
nancy in patients with systemic lupus erythematosus. Taiwan J Ob-
stet Gynecol 2006; 45: 120-3. 
[58]  Tan LK, Tan HK, Lee CT, Tan AS. Outcome of pregnancy in 
Asian women with systemic lupus erythematosus: experience of a 
single perinatal centre in Singapore. Ann Acad Med Singapore 
2002; 31: 290-5. 
[59]  De Bandt M, Palazzo E, Belmatoug N, et al. Outcome of pregnan-
cies in lupus: experience at one center. Ann Med Interne (Paris) 
2000; 151: 87-92. 
[60]  Carmona F, Font J, Cervera R, Munoz F, Cararach V, Balasch J. 
Obstetrical outcome of pregnancy in patients with systemic Lupus 
erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod 
Biol 1999; 83: 137-42. 
[61]  Derksen RH, Bruinse HW, de Groot PG, Kater L. Pregnancy in 
systemic lupus erythematosus: a prospective study. Lupus 1994; 3: 
149-55. 
[62]  Buyon J, Wallace D. The endocrine system, use of exogenous 
estrogens, and the urogenital tract, in Dubois' lupus erythematosus. 
B. Hahn, Ed., Williams & Wilkins: Baltimore, 1997, pp. 817-834. 
[63]  Langevitz P, Klein L, Pras M, Many A. The effect of cyclophos-
phamide pulses on fertility in patients with lupus nephritis. Am J 
Reprod Immunol 1992; 28: 157-8. 
[64]  Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel 
JH, Balow JE. Risk for sustained amenorrhea in patients with sys-
temic lupus erythematosus receiving intermittent pulse cyclophos-
phamide therapy. Ann Intern Med 1993; 119: 366-9. 
[65]  McDermott EM, Powell RJ. Incidence of ovarian failure in sys-
temic lupus erythematosus after treatment with pulse cyclophos-
phamide. Ann Rheum Dis 1996; 55: 224-9. 
[66]  Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in 
patients with systemic lupus erythematosus receiving cyclophos-
phamide therapy. Arthritis Rheum 1998; 41: 831-7. 
[67]  Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and 
fertility after intravenous cyclophosphamide. A study in 84 pa-
tients. J Rheumatol 2002; 29: 2571-6. 
[68]  Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Pre-
dictors of sustained amenorrhea from pulsed intravenous cyclo-
phosphamide in premenopausal women with systemic lupus 
erythematosus. J Rheumatol 2002; 29: 2129-35. 98    The Open Rheumatology Journal, 2008, Volume 2  Yuen et al. 
[69]  Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. 
Preserving ovarian function in patients receiving cyclophos-
phamide. Lupus 1999; 8: 3-10. 
[70]  Blumenfeld Z. Preservation of fertility and ovarian function and 
minimalization of chemotherapy associated gonadotoxicity and 
premature ovarian failure: the role of inhibin-A and -B as markers. 
Mol Cell Endocrinol 2002; 187: 93-105. 
[71]  Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preser-
vation of fertility and ovarian function and minimizing gonadotox-
icity in young women with systemic lupus erythematosus treated 
by chemotherapy. Lupus 2000; 9: 401-5. 
[72]  Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, 
Sammaritano LR. OC-SELENA Trial. Combined oral contracep-
tives in women with systemic lupus erythematosus. N Engl J Med 
2005; 353 (24): 2550-8. 
[73]  Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, et al. 
Menopause hormonal therapy in women with systemic lupus 
erythematosus. Arthritis Rheum 2007; 56 (9): 3070-9. 
[74]  Dhar JP, Essenmacher LM, Ager JW, Sokol RJ. Pregnancy out-
comes before and after a diagnosis of systemic lupus erythemato-
sus. Am J Obstet Gynecol 2005; 193: 1444-55. 
[75]  Mok MY, Leung PY, Lao TH, et al. Clinical predictors of fetal and 
maternal outcome in Chinese patients with systemic lupus erythe-
matosus. Ann Rheum Dis 2004; 63: 1705-6. 
[76]  Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin 
antibody testing and attempted standardization has led us to here, 
which is? Semin Thromb Hemost 2008; 34 (4): 313-28. 
[77]  Ramsey-Goldman R, Kutzer JE, Kuller LH, Guzick D, Carpenter 
AB, Medsger TA, Jr. Pregnancy outcome and anti-cardiolipin anti-
body in women with systemic lupus erythematosus. Am J Epide-
miol 1993; 138: 1057-69. 
[78]  Khamashata M, Gil M, Pascual D. Antiphospholipid antibodies in 
SLE. Clinical association. Clin Exp Rheumatol 1988; 6: 205A. 
[79]  Kutteh WH, Ermel LD. A clinical trial for the treatment of an-
tiphospholipid antibody-associated recurrent pregnancy loss with 
lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35 
(4): 402-7. 
[80]  Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of 
aspirin and aspirin plus heparin in pregnant women with recurrent 
miscarriage associated with phospholipid antibodies (or antiphos-
pholipid antibodies). BMJ 1997; 314 (7076): 253-7. 
[81]  Erkan D, Patel S, Nuzzo M, et al. Management of the controversial 
aspects of the antiphospholipid syndrome pregnancies: a guide for 
clinicians and researchers. Rheumatology (Oxford) 2008; 47 (Suppl 
3): iii23-7. 
[82]  Petri M, Howard D, Repke J, Goldman DW. The Hopkins Lupus 
Pregnancy Center: 1987-1991 update. Am J Reprod Immunol 
1992; 28: 188-91. 
[83]  Johnson MJ, Petri M, Witter FR, Repke JT. Evaluation of preterm 
delivery in a systemic lupus erythematosus pregnancy clinic. Ob-
stet Gynecol 1995; 86: 396-9. 
[84]  Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and 
aspirin in women with autoantibodies and unexplained recurrent fe-
tal loss. N Engl J Med 1997; 337: 148-53. 
[85]  Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. 
Repeated fetal losses associated with antiphospholipid antibodies: a 
collaborative randomized trial comparing prednisone with low-dose 
heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-23. 
[86]  Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, 
Ragin A. Comparative trial of prednisone plus aspirin versus aspi-
rin alone in the treatment of anticardiolipin antibody-positive ob-
stetric patients. Am J Obstet Gynecol 1993; 169 (6): 1411-7. 
[87]  Lockshin MD. Lupus pregnancies and neonatal lupus. Springer 
Semin Immunopathol 1994; 16: 247-59. 
[88]  Jara-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hor-
mones during pregnancy in systemic lupus erythematosus. J Rheu-
matol 1991; 18: 349-53. 
[89]  McMurray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. 
Longstanding hyperprolactinemia associated with systemic lupus 
erythematosus: possible hormonal stimulation of an autoimmune 
disease. J Rheumatol 1994; 21: 843-50. 
[90]  Pauzner R, Urowitz MB, Gladman DD, Gough JM. Prolactin in 
systemic lupus erythematosus. J Rheumatol 1994; 21: 2064-7. 
[91]  Buskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No 
correlation between prolactin levels and clinical activity in patients 
with systemic lupus erythematosus. J Rheumatol 1996; 23: 629-32. 
[92]  Ostendorf B, Fischer R, Santen R, Schmitz-Linneweber B, Specker 
C, Schneider M. Hyperprolactinemia in systemic lupus erythemato-
sus? Scand J Rheumatol 1996, 25: 97-102. 
[93]  Mok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese 
systemic lupus erythematosus patients. Br J Rheumatol 1997; 36: 
986-9. 
[94]  Leaños-Miranda A, Cárdenas-Mondragón G. Serum free prolactin 
concentrations in patients with systemic lupus erythematosus are 
associated with lupus activity. Rheumatology (Oxford) 2006; 45: 
97-101. 
[95]  Sugiura K, Muro Y, Watanabe A, Tomita Y. A case of systemic 
lupus erythematosus: continued association of circulating prolactin 
levels with disease activity over a 4-year follow-up period. Mod 
Rheumatol 2005; 15 (3): 220-2. 
[96]  Mok CC, Wong RW, Lau CS. Exacerbation of systemic lupus 
erythematosus by breast feeding. Lupus 1998; 7: 569-70. 
[97]  Weetman AP, Walport MJ. The association of autoimmune thy-
roiditis with systemic lupus erythematosus. Br J Rheumatol 1987; 
26: 359-61. 
[98]  Pyne D, Isenberg DA. Autoimmune thyroid disease in systemic 
lupus erythematosus. Ann Rheum Dis 2002; 61: 70-2. 
[99]  Mader R, Mishail S, Adawi M, Lavi I, Luboshitzky R. Thyroid 
dysfunction in patients with systemic lupus erythematosus (SLE): 
relation to disease activity. Clin Rheumatol 2007; 26 (11): 1891-4. 
 
 
Received: October 31, 2008  Revised: November 12, 2008  Accepted: December 16, 2008 
 
© Yuen et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
 